Tiziana Life Sciences (NASDAQ:TLSA) CEO Purchases $237,616.00 in Stock

Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi acquired 237,616 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was bought at an average cost of $1.00 per share, for a total transaction of $237,616.00. Following the purchase, the chief executive officer directly owned 4,793,684 shares of the company’s stock, valued at approximately $4,793,684. This trade represents a 5.22% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ivor Elrifi also recently made the following trade(s):

• On Tuesday, August 4th, Ivor Elrifi bought 83,807 shares of Tiziana Life Sciences stock. The stock was purchased at an average cost of $0.97 per share, for a total transaction of $81,292.79.
• On Monday, August 3rd, Ivor Elrifi purchased 667,000 shares of Tiziana Life Sciences stock. The shares were acquired at an average cost of $1.00 per share, with a total value of $667,000.00.

Tiziana Life Sciences Stock Performance

TLSA opened at $1.00 on Friday. Tiziana Life Sciences Ltd has a 52-week low of $0.87 and a 52-week high of $2.53. The firm’s 50-day moving average price is $1.13 and its 200-day moving average price is $1.30.

Wall Street Analysts Forecast Growth

TLSA has been the topic of a number of analyst reports. Zacks Research upgraded Tiziana Life Sciences to a “hold” rating in a research report on Tuesday, July 14th. Wall Street Zen cut shares of Tiziana Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, April 18th. Finally, Weiss Ratings downgraded Tiziana Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 29th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Tiziana Life Sciences presently has an average rating of “Reduce”.

Institutional Trading of Tiziana Life Sciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Bison Wealth LLC purchased a new stake in Tiziana Life Sciences during the 4th quarter worth approximately $30,000. Millennium Management LLC purchased a new position in shares of Tiziana Life Sciences in the 3rd quarter valued at about $520,000. Marshall Wace LLP increased its stake in Tiziana Life Sciences by 5.2% in the fourth quarter. Marshall Wace LLP now owns 282,017 shares of the company’s stock valued at $420,000 after purchasing an additional 14,005 shares during the last quarter. Jane Street Group LLC raised its stake in Tiziana Life Sciences by 968.2% during the 1st quarter. Jane Street Group LLC now owns 167,542 shares of the company’s stock worth $181,000 after acquiring an additional 151,858 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Tiziana Life Sciences by 413.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 110,290 shares of the company’s stock valued at $164,000 after purchasing an additional 88,830 shares during the last quarter.

About Tiziana Life Sciences

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small?molecule program, milciclib, is an oral cyclin?dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.